We are live on ! Find out more
DTIL icon

Precision BioSciences

134 hedge funds and large institutions have $233M invested in Precision BioSciences in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 30

2% more funds holding

Funds holding: 132134 (+2)

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

7% more call options, than puts

Call options by funds: $567K | Put options by funds: $530K

0.1% more ownership

Funds ownership: 1.63%1.73% (+0.1%)

31% less capital invested

Capital invested by funds: $337M → $233M (-$103M)

Holders
134
Holders Change
+2
Holders Change %
+1.52%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
48
Reduced
30
Closed
24
Calls
$567K
Puts
$530K
Net Calls
+$37K
Net Calls Change
-$1.13M

DTIL Hedge Fund Activity: Q4 2021 in Review

134 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q4 2021, worth a combined $233M — down 31% from $337M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new DTIL positions and 24 closed out — a net gain of 2 holders — while 48 added to existing stakes and 30 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $2.84M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $3.97M.

  • 134 institutional investors held Precision BioSciences (DTIL) as of Q4 2021, up from 132 in Q3 2021.
  • Funds reported $233M of Precision BioSciences stock for Q4 2021, down 31% quarter-over-quarter.
  • 26 funds opened new Precision BioSciences positions in Q4 2021 and 24 closed out, a net change of +2 holders.
  • The largest Precision BioSciences buyer in Q4 2021 was Goldman Sachs, an estimated $2.84M added.
  • The largest Precision BioSciences seller in Q4 2021 was ArrowMark Colorado Holdings, an estimated $3.97M sold.

Based on aggregated 13F filings for Q4 2021.